Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04361214 · ClinicalTrials.gov registry record · Phase 1
Leflunomide in Mild COVID-19 Patients
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT04361214 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 11 participants.
The verdict
NCT04361214, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are being managed in the outpatient setting.
Interventions
- DRUG Leflunomide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2020-05-05 |
| Est. Completion | 2022-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04361214
The ClinicalTrials.gov registry entry for NCT04361214 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Leflunomide is the first listed.
NCT04361214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04361214 about?
NCT04361214 is a clinical study titled "Leflunomide in Mild COVID-19 Patients". This study aims to examine the tolerability of high dose of leflunomide in patients with COVID-19 who are being managed in the outpatient setting.
What is the current status of trial NCT04361214?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2020-05-05. Estimated completion is 2022-01-31.
What interventions are being tested in trial NCT04361214?
The interventions under investigation include: Leflunomide (DRUG).
Who is sponsoring clinical trial NCT04361214?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.